Bridge™
The Bridge™ Intracranial Stent System is designed to provide exceptional support and stability for the treatment of complex cerebrovascular conditions. Engineered with precision and advanced technology, the Bridge™ stent ensures optimal performance in challenging clinical scenarios. Bridge™ features directional drug release, which enhances the safety and efficacy of the treatment by targeting the drug delivery precisely where it's needed.
Precision in Drug Loading
Drug storage is confined to the concave grooves on the outer surface of the stent, ensuring a lower drug load and higher safety.
Rapamycin Drug Coating with PLA Degradable Layer
Effectively reduces restenosis rates with higher safety compared to paclitaxel-coated devices. The degradable coating is absorbed within nine months, ensuring sustained drug release.
Directional Drug Release
Rapamycin is released towards the vascular endothelium, minimizing the impact on the surface of the stent and promoting safer integration, ensuring that the therapeutic effect is concentrated and efficient.
“S” + “-” Type Connections
The stent utilizes an “S” and “-” type connection, making it easier to bend axially and allowing for better apposition to the vessel walls.
n-Link Connectors
Minimizes axial shortening, ensuring more precise placement after deployment.
Clinical trial data show that for patients with severe vertebral artery stenosis, the Bridge™ stent system has demonstrated outstanding clinical outcomes, with a restenosis rate of only 3.7% within six months post-operation.
Product Specifications
Clinical Trail
“Safety and Efficacy of Rapamycin-Eluting Vertebral Stents in Patients With Symptomatic Extracranial Vertebral Artery Stenosis" evaluates the use of rapamycin-eluting stents in treating symptomatic extracranial vertebral artery stenosis (VAS). This prospective, multicenter, single-arm study aimed to assess the rate of in-stent restenosis (ISR) at 6 months and overall safety outcomes at 12 months. The trial demonstrated a low ISR rate of 5.9% at 6 months and showed favorable safety results, including low rates of perioperative complications and late strokes.